Abstract: A full-hydraulic chain reversing and remote control water-power harvesting equipment for lotus roots includes a main framework, a traveling module, an elevating module, and a working module. The main framework is of a two-cross-beam structure; the working module is of a skid-mounted structure; the working module is in transmission connection with the traveling module through the elevating module and is fixedly mounted on a top surface of the main framework; the traveling module includes caterpillar bands and a two-hydraulic-motor group; the two-hydraulic-motor group is in transmission connection with the caterpillar bands; the caterpillar bands and the two-hydraulic-motor group are fixedly mounted on a bottom cross beam of the main framework; and the working module includes a power driving module, a jet working module, a water suction pipeline module and a hydraulic power module.

Abstract: A preparation method of a heat-not-burn cigarette paper with boron nitride as a thermally-conductive filler includes: mixing potassium oleate, polyvinyl alcohol (PVA) and water, thoroughly stirring under an ultrasonic condition, aging, and filtering until there is no precipitate; thoroughly mixing a resulting mixed solution with a softwood pulp and a hardwood pulp to obtain a coarse pulp; and under stirring, adding boron nitride and calcium carbonate as a filler to the coarse pulp, heating to 60° C., and stirring for thorough mixing to obtain a pulp for sizing and papermaking. The present disclosure effectively improves the stability of a cigarette paper by improving a coefficient of thermal conductivity of the paper. Boron nitride, when used as a thermally-conductive filler in a thin-walled or paper product, enables high heat removal capacity. The preparation method retains the original whiteness and transparency of the cigarette paper, and provides high conductivity.

Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.

Abstract: A biodegradable film comprises from 1 wt % to 10 wt % of a first polyhydroxyalkanoate resin component, from 50 wt % to 90 wt % of a second polyhydroxyalkanoate resin component, and from 5 wt % to 48 wt % of a polybutylene adipate terephthalate resin. Specifically, the first poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) resin contains a first mol % of 3-hydroxyhexanoate structural units, and the second poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) resin contains a second mol % of 3-hydroxyhexanoate structural units, while the second mol % is higher than the first mol %, e.g., by 2-40 mol %, or 3-30 mol %, or 4-20 mol %.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: The invention relates to methods of treating inflammatory bowel diseases, including with engineered peptides (e.g. peptide monomers and dimers comprising disulfide or thioether intramolecular bonds) that bind ?4?7 integrin. In one aspect, the disclosure provides a method of treating an inflammatory bowel disease (IBD) in a subject in need thereof, comprising administering to the subject an ?4?7 integrin antagonist, wherein the antagonist is administered to the patient orally at a dose of about 100 mg to about 500 mg, once or twice daily, wherein the antagonist is a peptide dimer compound comprising two peptides, or a pharmaceutically acceptable salt thereof.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases, are described.

Abstract: The present invention provides methods for determining levels of biomarkers of inflammation in samples from human patients, e.g., patients undergoing treatment with a peptide inhibitor of interleukin-23 receptor. Such methods are useful, for example, in monitoring the therapeutic effect of treatment of an inflammatory disease or disorder with a peptide inhibitor of interleukin-23 receptor.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

Abstract: The present invention provides novel peptide inhibitors of interleukin-23, and related methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, Crohn's disease and psoriasis.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.